---
format:
  revealjs:
    touch: true
    controls: true
    transition: fade
    transition-speed: fast
    scrollable: true
    slide-number: false
    incremental: false
    multiplex: true
    chalkboard: true
    theme: [default, custom.scss]
    seal: false
bibliography: references.bib
---

## Adapting Bloodculture Systems to Monitor Antimicrobial Efficacy {background-image="/slides/bactec_background.png"}

<br>

![](acute_logo.png){fig-align="center" width="350"}

**Principle Investigator:** Irene Zaghi, M.D.

**Supervisors:**

-   Russell E. Lewis, Pharm.D., University of Padua
-   Monica Cricca, M.D., Ph.D., University of Bologna
-   Vittorio Sambri, M.D., Ph.D., Univeristy of Bologna

::: aside
January 20, 2023
:::

## Antibiotic dosing is an uncertain science

![](meropenem_resistance.png){fig-align="center" width="400"}

::: aside
Image: Irene Zaghi, M.D.
:::

## Antibiotic dosing is an uncertain science

<br>

![](pkpd1.png){fig-align="center" width="600"}

::: aside
[@theuretzbacher2012; @Roberts2014]
:::

## Antibiotic dosing is an uncertain science

<br>

![](pkpd2.png){fig-align="center" width="800"}

::: aside
[@theuretzbacher2012; @Roberts2014]
:::

## How can dosing uncertainty be managed?

![](dose_individual.png){fig-align="center" width="800"}

::: aside
[@Roberts2014]
:::

## Dosing uncertainty at the dawn of penicillin resistance

![](schlichter.png){fig-align="center" width="600"}

::: aside
[@schlichter_maclean47]
:::

## Dosing uncertainty at the dawn of penicillin resistance

<br>

<br>

> "It was felt that there was a need of some definite basis for determining adequate therapy for each specific infectious organism involved..."

> "Current methods in general use all depend on indirect comparisons (MICs, measurement of penicillin blood levels). In patients with more resistant organisms, it has not been demonstrated that this is the proper approach..."

> "...It occurred to us that a more satisfactory method of outlining adequate therapy in resistant organisms might be based on the action of the patient's own serum during penicillin administration."

::: aside
[@schlichter_maclean47]
:::

## Serum bactericidal test (SBT)

![](M21A%20method.png){fig-align="center" width="800"}

::: aside
[@clsi99; @zaghi_etal20]
:::

## SBTs correlate with antibiotic PK/PD

![](Meropenem%20SBT.png){fig-align="center"}

::: aside
[@zaghi_etal20]
:::

## Potential clinical utility of SBTs

### Individual patient-level diagnostic meta-analysis (1947-2020)

![](metaanalysis.png){fig-align="center" width="800"}

Prognostic performance similar or better than current susceptibility breakpoints

::: aside
[@zaghi_etal20]
:::

## SBTs advantages

<br>

-   Only microbiological test that accounts for both antibiotic PK and PD
-   Theoretically accounts for protein binding changes
-   Can detect synergistic or antagonistic interactions

## Why were SBTs abandoned?
<br>

-   Insufficent standardization despite published methods (CLSI M21-A, last updated 1999)
-   Poor inter-laboratory reproducibility
-   Labour-intensive to perform
-   Lack of perceived need in 1990s (reliably bactericidal antibiotics)
-   **Delay in results reporting (48-72 hours with patients isolate)**


## "I read your SBT review and have a suggestion..."

#### Use continuously-monitored bloodculture systems Time-to-positivity (Tpos) to measure bactericidal activity

Concept: The assay measures the time taken for a standardized bacterial inoculum to "grow through" the antimicrobial activity in the patient's serum under defined conditions.

![](Cohen.png){fig-align="center" width="800"}

::: aside
-   A short Tpos would indicate inadequate antimicrobial activity and should predict a worse outcome
-   A long Tpos is evidence of adequate antimicrobial activity and should predict a good outcome
:::

## Blood culture Tpos measures bacterial inoculum and antimicrobial pharmacokinetics

<br>

<center>A "critical" Tpos result could be reported in \< 12 hours!</center>

![](cohendata.png){fig-align="center"}

::: aside
[@kaltsas2005; @jerwood2012]
:::

## Adapting Bloodculture Systems to Monitor Antimicrobial Efficacy {background-image="/slides/bactec_background.png"}

![](acute_logo.png){fig-align="center" width="200"}

<br>

<br>

-   **Specific Aim# 1:** Establish the quantitative relationship *in vitro* between Tpos and carbapenamase-producing Enterobacterales (CPE) and define antibiotic concentration-effect relationships
-   **Specific Aim#2**: Pilot observational clinical study in 20 septic patients undergoing treatment for CPE to explore how early Tpos results with "indicator" isolates correlate with individual antibiotic PK/PD targets

## Tpos correlates with inoculum {.smaller}

::: panel-tabset
### K. pneumoniae

```{r, .smaller}

library (ggplot2)
library(scales)
theme_set(theme_bw())
## import raw data from .csv file
wp1 <- read.csv("~/Desktop/ACUTEWEBSITE/wp1a.csv")
## plot raw data as x-y graph Tpos graph vs. drug concentrations stratified by dilution matrix, method="lm" is the method for linear regression
fig1 <-ggplot(wp1, aes(x=inoculum, y=tpos, color=isolates, shape=diluent, fill=isolates)) + geom_point(size=4, alpha = 0.5) + 
scale_y_continuous(name="Tpos (hr)", limits=c(4,12)) +
theme(legend.text=element_text(size=12)) +
geom_smooth(aes(linetype=diluent), method=lm , color="black", fill="#69b3a2", se=TRUE, inherit.aes = TRUE )
kpc<-fig1 + theme_bw(base_size = 14)+ scale_x_log10(name="Inoculum CFU/mL", breaks = trans_breaks("log10",n=7, function(x) 10^x),labels = trans_format("log10", math_format(10^.x)))
plot(kpc)
```

### E. coli

```{r}
library (readxl)
library (ggplot2)
library(scales)
theme_set(theme_bw())
## plot raw data as x-y graph Tpos graph vs. drug concentrations stratified by dilution matrix, method="lm" is the method for linear regression
ecoliatcc_inoc <- read_excel("~/Desktop/ACUTEWEBSITE/datasets_single/ecoliatcc_inoculum.xlsx")
figecoli <-ggplot(ecoliatcc_inoc, aes(x=inoculum, y=tpos)) + geom_point(size=4, alpha = 0.5) + 
scale_y_continuous(name="Tpos (hr)", limits=c(4,12)) +
theme(legend.text=element_text(size=12)) +
geom_smooth(aes(linetype=diluent), method=lm , color="black", fill="#69b3a2", se=TRUE, inherit.aes = TRUE )
ecoli<- figecoli + theme_bw(base_size = 14)+ scale_x_log10(name="Inoculum CFU/mL", breaks = trans_breaks("log10",n=7, function(x) 10^x),labels = trans_format("log10", math_format(10^.x)))
plot (ecoli)
```

### A. baumanii

```{r}
library (ggplot2)
library(scales)
theme_set(theme_bw())
## import raw data from .csv file
library (readxl)
abaumani <- read_excel("~/Desktop/ACUTEWEBSITE/abaum_pbs.xlsx")
## plot raw data as x-y graph Tpos graph vs. drug concentrations stratified by dilution matrix, method="lm" is the method for linear regression
abaumi<-ggplot(abaumani, aes(x=inoculum, y=tpos)) + geom_point(size=4, alpha = 0.5) + 
scale_y_continuous(name="Tpos (hr)", limits=c(4,12)) +
theme(legend.text=element_text(size=12)) +
geom_smooth(aes(linetype=diluent), method=lm , color="black", fill="#69b3a2", se=TRUE, inherit.aes = TRUE )
abaumi2 <-abaumi+ theme_bw(base_size = 14)+ scale_x_log10(name="Inoculum CFU/mL", breaks = trans_breaks("log10",n=7, function(x) 10^x),labels = trans_format("log10", math_format(10^.x)))
plot (abaumi2)
```

### P. aeruginosa

```{r}
library (ggplot2)
library(scales)
theme_set(theme_bw())
## import raw data from .csv file
library (readxl)
pseudo <- read_excel("~/Desktop/ACUTEWEBSITE/pseudo_pbs.xlsx")
## plot raw data as x-y graph Tpos graph vs. drug concentrations stratified by dilution matrix, method="lm" is the method for linear regression
fig2f <-ggplot(pseudo, aes(x=inoculum, y=tpos, color=isolates, fill=isolates)) + geom_point(size=4, alpha = 0.5) + 
scale_y_continuous(name="Tpos (hr)", limits=c(4,12)) +
theme(legend.text=element_text(size=12)) +
geom_smooth(aes(linetype=diluent), method=lm , color="black", fill="#69b3a2", se=TRUE, inherit.aes = TRUE )
psa <-fig2f + theme_bw(base_size = 14)+ scale_x_log10(name="Inoculum CFU/mL", breaks = trans_breaks("log10",n=7, function(x) 10^x),labels = trans_format("log10", math_format(10^.x)))
plot(psa)
```
:::

R^2^ = 0.96-0.99

## Tpos can descriminate between susceptible and resistant pathogens

```{r}

library (ggplot2)
theme_set(theme_bw())
ceftaz <- read.csv("~/Desktop/ACUTEWEBSITE/datasets_single/ceftazidime.csv")
ggplot(ceftaz, aes(x=conc_s, y=tpos, color=isolate, shape=isolate)) + 
  geom_point(size=4, alpha = 0.7) + 
  geom_smooth(aes(linetype=isolate), method= loess, color="black", fill="#69b3a2", se=TRUE, inherit.aes = TRUE ) +
scale_x_log10(name="CAZ/AVI conc, mg/L") +
scale_y_continuous(name="Tpos (hr)", limits=c(4,25)) 
```

::: aside
KPC_B MIC 1.0 mg/L, KPC_NDM MIC > 256 mg/L; data fit byLoess
:::

## References

<br>
